RITUXAN and AVASTIN do not infringe Sanofi’s CMV enhancer patents
The Court of Appeals for the Federal Circuit recently upheld a summary judgement decision that neither rituximab nor trastuzumab infringes two Sanofi...Read More
Quetiapine Formulation Patent Obvious – U.K. High Court
On March 22, 2012, the U.K. High Court of Justice, Chancery Division held that AstraZeneca’s patent covering an sustained release formulation of...Read More
Centocor’s ustekinumab infringes Abbott’s human IL-2 antibody patents – US District Judge
On March 9, 2012, the District Court of Massachusetts found, within a series of competing summary judgement motions, that Centocor’s ustekinumab (STELARA)...Read More